New hope for tough prostate cancer: targeted radiation after other treatments fail
NCT ID NCT06402331
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests a new drug, FPI-2265, which delivers targeted radiation to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and who have already had a similar type of radiation treatment. The goal is to find the safest and most effective dose and to see if it can shrink tumors or lower PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Biogenix Molecular, LLC
Miami, Florida, 33165, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Hoag Health Center Irvine
Irvine, California, 92618, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Memorial Sloan Kettering Cancer Center - NYC
New York, New York, 10065, United States
-
New Mexico Oncology Hematology Consultants Ltd.
Albuquerque, New Mexico, 87109, United States
-
Oregon Health and Science University (OHSU, Knight Cancer Center)
Portland, Oregon, 97239-3098, United States
-
SSM Health Saint Louis University Hospital
St Louis, Missouri, 63104, United States
-
The University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
U.T. MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSF School of Medicine
San Francisco, California, 94143, United States
-
United Theranostics
Glen Burnie, Maryland, 21061, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
VA Greater Los Angeles Healthcare System
Los Angeles, California, 90073, United States
-
VA North Texas Health Care System, Nuclear Medicine Service
Dallas, Texas, 75216, United States
-
XCancer
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.